A PHASE II, RANDOMIZED, MULTICENTER STUDY TO ASSESS THE EFFICACY OF NAB-PACLITAXEL-BASED DOUBLET AS FIRST LINE THERAPY IN PATIENTS WITH CANCER OF UNKNOWN PRIMARY (CUP): the AGNOSTOS trial

Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2020
This article has no abstract
Epistemonikos ID: 7d1eca4ea450df8014d97535154051d7877d0b38
First added on: Jan 22, 2025